Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Robeco Institutional Asset Management B.V.

by · The Cerbat Gem

Robeco Institutional Asset Management B.V. boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 153.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 120,884 shares of the biopharmaceutical company’s stock after purchasing an additional 73,176 shares during the period. Robeco Institutional Asset Management B.V. owned approximately 0.11% of Regeneron Pharmaceuticals worth $67,969,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Dodge & Cox increased its position in shares of Regeneron Pharmaceuticals by 64.6% in the 2nd quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock valued at $2,008,799,000 after acquiring an additional 1,502,198 shares during the period. Norges Bank purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at about $628,151,000. Acadian Asset Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 234.7% in the second quarter. Acadian Asset Management LLC now owns 465,740 shares of the biopharmaceutical company’s stock valued at $244,480,000 after purchasing an additional 326,583 shares during the period. Loomis Sayles & Co. L P increased its holdings in shares of Regeneron Pharmaceuticals by 18.6% in the second quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock valued at $1,019,062,000 after purchasing an additional 305,089 shares during the period. Finally, Invesco Ltd. raised its stake in shares of Regeneron Pharmaceuticals by 26.5% in the second quarter. Invesco Ltd. now owns 1,075,824 shares of the biopharmaceutical company’s stock worth $564,808,000 after purchasing an additional 225,078 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling

In other news, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the sale, the vice president directly owned 4,233 shares in the company, valued at $2,757,503.19. The trade was a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Christine A. Poon sold 6,500 shares of the stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the transaction, the director owned 2,352 shares in the company, valued at $1,538,843.04. This trade represents a 73.43% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is owned by insiders.

Regeneron Pharmaceuticals Trading Up 1.7%

Shares of Regeneron Pharmaceuticals stock opened at $776.54 on Wednesday. The firm has a 50-day simple moving average of $729.10 and a two-hundred day simple moving average of $623.54. The company has a market cap of $81.61 billion, a P/E ratio of 18.60, a price-to-earnings-growth ratio of 2.28 and a beta of 0.39. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $792.77. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.33 and a current ratio of 4.06.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last posted its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. During the same period last year, the firm earned $12.46 EPS. The company’s quarterly revenue was up .9% on a year-over-year basis. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Thursday, November 20th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.43%.

Wall Street Analyst Weigh In

A number of brokerages recently commented on REGN. UBS Group upped their target price on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Truist Financial started coverage on shares of Regeneron Pharmaceuticals in a research note on Monday, November 24th. They set a “buy” rating and a $798.00 price objective for the company. Wells Fargo & Company upped their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the company an “equal weight” rating in a report on Wednesday, December 10th. Bank of America raised their target price on shares of Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the stock an “underperform” rating in a report on Wednesday, October 29th. Finally, HSBC started coverage on shares of Regeneron Pharmaceuticals in a report on Monday, November 24th. They issued a “buy” rating and a $255.00 price target on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $779.45.

Get Our Latest Analysis on REGN

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Featured Articles